| 产品编号 | bs-1905R |
| 英文名称 | Synphilin-1 Rabbit pAb |
| 中文名称 | 核突触蛋白相互作用蛋白1抗体 |
| 别 名 | Synphilin-1; Synphilin1; Synphilin 1; alpha-synuclein-interacting protein; Sncaip; Syph1, Syph 1, Syph-1; alpha synuclein interacting protein; MGC39814; SNCAIP; SNCAP_HUMAN; Sph1; Synuclein alpha interacting protein(synphilin); SYPH 1. |
 |
Specific References (1) | bs-1905R has been referenced in 1 publications.
[IF=5.808] Guo Q et al. Small interfering RNA delivery to the neurons near the amyloid plaques for improved treatment of Alzheimer's disease. Acta Pharm Sin B. 2019 May;9(3):590-603. WB ; Mouse.
|
| 研究领域 | 细胞生物 免疫学 神经生物学 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 克 隆 号 | |
| 交叉反应 | Rat (predicted: Human,Mouse,Rabbit,Pig,Sheep,Cow,Chicken,Dog,GuineaPig,Horse) |
| 产品应用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 100 kDa |
| 检测分子量 | |
| 细胞定位 | 细胞浆 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Synphilin-1: 51-150/919 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
This gene encodes a protein containing several protein-protein interaction domains, including ankyrin-like repeats, a coiled-coil domain, and an ATP/GTP-binding motif. The encoded protein interacts with alpha-synuclein in neuronal tissue and may play a role in the formation of cytoplasmic inclusions and neurodegeneration. A mutation in this gene has been associated with Parkinson's disease. Alternatively spliced transcript variants encoding different isoforms of this gene have been described, but the full-length nature of only two have been determined. [provided by RefSeq, Jul 2011]. Function: Isoform 2 inhibits the ubiquitin ligase activity of SIAH1 and inhibits proteasomal degradation of target proteins. Isoform 2 inhibits autoubiquitination and proteasomal degradation of SIAH1, and thereby increases cellular levels of SIAH. Isoform 2 modulates SNCA monoubiquitination by SIAH1. Subunit: Homodimer (Probable). Heterodimer of isoform 1 and isoform 2 (Probable). Interacts with SIAH1, SIAH2, SNCA, RNF19A AND PARK2. Isoform 2 has a strong tendency to form aggregates and can sequester isoform 1. Subcellular Location: Cytoplasm. Detected in cytoplasmic inclusion bodies, together with SNCA. Tissue Specificity: Detected in brain (at protein level). Widely expressed, with highest levels in brain, heart and placenta. Post-translational modifications: Ubiquitinated; mediated by SIAH1, SIAH2 or RNF19A and leading to its subsequent proteasomal degradation. In the absence of proteasomal degradation, ubiquitinated SNCAIP accumulates in cytoplasmic inclusion bodies. Isoform 2 is subject to limited ubiquitination that does not lead to proteasomal degradation. DISEASE: Parkinson disease (PARK) [MIM:168600]: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features. Note=Disease susceptibility may be associated with variations affecting the gene represented in this entry. Similarity: Contains 6 ANK repeats. SWISS: Q9Y6H5 Gene ID: 9627 Database links: Entrez Gene: 9627 Human Entrez Gene: 67847 Mouse Omim: 603779 Human SwissProt: Q9Y6H5 Human SwissProt: Q99ME3 Mouse Unigene: 426463 Human Unigene: 292168 Mouse |
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
